The mean IL-6 level in patients was nearly 2.5 times higher than in controls, indicating a robust inflammatory response associated with the presence of bladder cancer, which makes IL-6 a strong candidate as both a prognostic marker and a therapeutic target. This evidence concerns the gene IL6 and urinary bladder carcinoma.